Purpose: To evaluate the ef®cacy of sertraline hydrochloride in the drug treatment of premature ejaculation (P.E.). Materials and Method: Forty-six normally potent men, aged 22 to 63 years (mean 42 years) with premature ejaculation were treated with oral sertraline in a dose ranging study. All men were either married or in a stable relationship. The mean ejaculatory interval was 1 minute (range 0± 5 min). All men were started on Sertraline 25 mg daily and were increased to 50 mg after 3 weeks and 100 mg after a further 3 weeks. None of the men received any formal psychosexual therapy. Results: With a dose of 25 mg, the mean ejaculatory interval increased to 7.6 min (range 0±20 min). With a dose of 50 mg, the mean ejaculatory interval increased to 13.1 min (range 7 min± anejaculation) with 4 men experiencing anejaculation. With a dose of 100 mg, the mean ejaculatory interval increased to 16.4 min (range 7 min±anejaculation), 10 men experiencing anejaculation. With a dose of 25 mg, 1 man described transient dizziness. With a dose of 50 mg, 1 man described some drowsiness and anorexia and 1 man experienced minor dyspepsia. With a dose of 100 mg, 2 men described erectile dysfunction and reduced libido, 2 men described transient drowsiness and anorexia, 2 men experienced minor dyspepsia and 2 men described feelings of anxiety. Conclusion: Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation.
Introduction
Premature ejaculation (PE) is the most common male sexual disorder, affecting perhaps as many as 75% of men at some stage in their sexual lives. The Diagnostic and Statistical Manual of Psychiatry (DSM-IV) de®nes premature ejaculation as`ejaculation that occurs before the individual wishes because of recurrent and persistent lack of reasonable voluntary control of ejaculation and orgasm during sexual activity F F F'. 1 Premature ejaculation is invariably psychogenic and can be due to performance anxiety, fear or psychological trauma. Men with premature ejaculation progress very rapidly from excitement to orgasm which is often experienced as minimally pleasurable. They appear to have a hypersensitive ejaculatory re¯ex. The fact that anxiety plays a role in this process however, is attested by the frequent situational nature of the problem and the almost universal experience of good ejaculatory control during solitary masturbation.
Although the`cornerstone' of treatment is short term directive sex therapy, premature ejaculation may also be treated pharmacologically with a variety of different medications. These medications either act centrally or locally to retard the psychoneurological control of ejaculation and subsequent orgasm. It is well established that major tranquillisers such as the phenothiazine, thioridazine, will retard ejaculation signi®cantly and will, in a signi®cant percentage of men result in failure to ejaculate. 2 Although these agents can be used to treat PE their ef®cacy is unfortunately counteracted by the high incidence of adverse side effects including drowsiness, tardive dyskinesia and other extrapyramidal adverse effects. The antidepressant clomipramine is often associated with delayed or absent ejaculation with an incidence of up to 94% 3, 4 and has been reported as useful in the treatment of PE. 5, 6 The selective serotonin re-uptake inhibitors (SSRIs) are primarily indicated in the treatment of depression and are often associated with a variety of sexual adverse reactions including delayed ejaculation. The side effect pro®le differs between different SSRIs,¯uoxetine tending to effect ejaculation, orgasm and sexual desire, all of which are restored slowly after withdrawal of the drug, whereas sertraline and paroxetine tend to affect ejaculation more. 
Materials and methods
Forty-six normally potent men, aged 22±63 y (mean 42 y) suffering from PE were enrolled in a prospective dose ranging study to assess the ef®cacy and tolerance of sertraline hydrochloride (Zoloft 1 ) in the management of PE. All of the study group were heterosexual, had no other sexual disorders and were either married or in a stable relationship.
Premature ejaculation was regarded as ejaculation that occurred earlier than either the man or his partner wished. As no attempt was made to enrol men using accepted average ejaculatory latency time intervals, several men had ejaculatory latency intervals that would be regarded as acceptable by normal standards. Men with erectile dysfunction, reduced sexual desire, inhibited male orgasm, chronic psychiatric or physical illness, alcohol or substance abuse and the use of psychotropic medication were excluded from the trial. Men were asked not to use condoms, topical penile anaesthetic creams or sprays. None of the men received any formal psychosexual counselling.
The study comprised three consecutive treatment phases each separated by a three week washout period. In treatment phase I, men received 25 mg sertraline daily for three weeks. Following completion of phase 1 and the subsequent drug washout period, men were enrolled in treatment phase 2 and received 50 mg sertraline daily for a further three weeks. Following completion of phase 2 and the subsequent drug washout period, men were enrolled in treatment phase 3 and received 100 mg sertraline daily for the ®nal three weeks.
Men were supplied with an ejaculation diary and were asked to record their frequency of coitus, quality of erection and orgasm, and to measure and record their ejaculatory latency time using a stopwatch. Men were required to attempt coitus on at least two occasions each week. Results were analysed using standard statistical methods.
Results
The mean age of the 46 men studied was 42 y (range 22±63 y). The mean pre-treatment ejaculatory latency time was 1.0 min with a range of ejaculation occurring from during foreplay or at intromission to 5 min after intromission. The pre-treatment frequency of intercourse was 0.6 timesaweek. Thirtysix men (78%) had primary premature ejaculation, the remaining 10 men (22%) describing secondary premature ejaculation with previous acceptable ejaculatory control. Of the 36 men with primary premature ejaculation, 6 men (17%) had severe primary premature ejaculation and had never achieved intravaginal ejaculation.
In treatment phase 1 (25 mg sertralinead), the mean ejaculatory latency time of the 46 enrolled men was 7.6 min (range 0±20 min). In treatment phase 2 (50 mg sertralinead) the mean ejaculatory latency time of the 46 enrolled men was 13.1 min (range 7 min anejaculation). Four men were unable to ejaculate after prolonged intercourse with 50 mg sertralinead and declined to enrol in treatment phase 3. In treatment phase 3 (100 mg sertralinead) the mean ejaculatory latency time of the 42 men enrolled was 16.4 min (range 7 min anejaculation). Ten men were unable to ejaculate after prolonged intercourse with 100 mg sertralinead ( Table 1) . The mean pre-treatment ejaculatory latency time of the 14 men who experienced anejaculation was 1.9 min (range 0±5 min).
The mean frequency of intercourse after three weeks of treatment was 1.6 timesaweek in treatment phase 1 (25 mg sertralinead), 2.1 timesaweek in treatment phase 2 (50 mg sertralinead) and 2.2 timesaweek in treatment phase 3 (100 mg sertralinead). The mean frequency of intercourse after three weeks of treatment was signi®cantly superior to the pre-treatment mean frequency with all doses of sertraline (p`0.001). There was no statistical difference between the mean frequency of intercourse with differing doses of sertraline.
Intravaginal ejaculation was achieved for the ®rst time in each of the cohort of six men with severe primary premature ejaculation who had never achieved intravaginal ejaculation. Intravaginal ejaculation occurred in four of the six men with 25 mg sertralinead and in all men with 50 mg and 100 mg sertralinead. The mean age of this group of six men Treatment of premature ejaculation CG McMahon was 26.9 years (range 23±32 years). All men in this cohort were either married or were involved in a long term stable relationship. One man in this cohort developed anejaculation with 100 mg sertralinead. Sertraline was, in general, well tolerated. Most side effects were minor and none prompted withdrawal from the study, apart from the anejaculation experienced by four and 10 men in treatment phase 2 and 3 respectively. With 25 mg sertralinead, one man described transient dizziness. With a dose of 50 mg sertralinead, one man described some minor drowsiness and anorexia and one man experienced minor dyspepsia. With a dose of 100 mg sertralinead, two men described erectile dysfunction and reduced libido, two men described transient drowsiness and anorexia, two men experienced minor dyspepsia and two men described feelings of anxiety ( Table 2 ).
Discussion
Many men decline or fail to complete a trial of psychosexual counselling for a variety of reasons. Men may decline treatment with psychosexual counselling as a result of their non-acceptance of counselling as a valid treatment due to incorrectly assumed social stigma associated with attending a psychiatrist or psychologist. Some men may be unable or not prepared to devote the time required to attend several counselling sessions. Other men may demand a quicker response than psychosexual counselling is reported to offer. Optimal results with psychosexual counselling are highly dependant on the cooperation of the sexual partner of the man in attending and actively participating in the counselling sessions. Many men do not have a current sexual partner or may have a non-compliant sexual partner. Clearly, a signi®cant treatment`hiatus' exists in the management of PE which may be ®lled by alternate non-counselling treatment methods.
Delayed ejaculation is a common side effect of many psychotropic and antidepressant drugs which act centrally or locally to retard the psychoneurological control of ejaculation and subsequent orgasm. Animal studies have shown that the central neurotransmitter serotonin has an inhibitory effect on sexual function, while dopamine is generally stimulatory. 7 Sexual effects can occur through any shift in this serotonin-dopamine balance by an increase or decrease in either or both neurotransmitter. The serotonin re-uptake inhibitors (SSRI) should reduce sexual excitement and have a bene®cial effect on premature ejaculation.
There Sertraline has a relatively long half life of 26 h allowing once daily dosing and promptly achieves peak plasma levels within 4±6 h. It undergoes extensive ®rst pass metabolism to the less active desmethylsertraline and its only contraindication, apart from known hypersensitivity, is the concurrent use of monoamine oxidase inhibitors. In addition to its selective serotonin inhibitory property, sertraline also appears to inhibit excitatory responses through blocking dopamine receptors and effecting amino acid sigma receptors, and by down regulating central b-adrenergic receptors. 15 The most common side effects are sexual and gastrointestinal but a very occasional man will experience the agitation and tremor seen with¯uoxetine.
This study demonstrates that sertraline prolongs the ejaculatory interval in a direct dose related fashion and increases the frequency of intercourse. The occurrence of anejaculation, the most common adverse effect of sertraline, is also dose related. Anejaculation was not observed with 25 mg sertralinead but did occur with dose escalation from 25 mg to 50 or 100 mg sertralinead. Delayed ejaculation and as a consequence, improved ejaculatory control, appears to occur within 1±2 weeks of initiating treatment. This acute effect is due to sertraline's direct blocking effect on central serotonergic re-uptake and cannot be attributed to a decrease in psychopathology since none of the men were clinically depressed. Furthermore, the antidepressant effect of sertraline has not been reported to occur within 1±2 weeks. As a signi®cant improvement in ejaculatory control was observed at doses as low as 25 mg and as anejaculation occurred in 10 out of 42 (24%) of men at a dose of 100 mg, it seems reasonable to suggest that sertraline treatment of PE be initiated at a dose of 25 mg and that the clinician should expect a satisfactory therapeutic response in most men with a dose of 25±50 mg. It is possible that any sustained long term improvement in ejaculatory control after withdrawal of sertraline could be related to a reduction in performance anxiety induced by the initial sertraline treatment related improvement in ejaculatory control and associated patientapartner perceived sexual success. The statistically signi®cant increase in the frequency of intercourse in patients treated with sertraline (1.6±2.2 timesaweek) compared to their pre-treatment frequency (0.6 timesaweek) is probably due to a reduction in the sexual avoidance commonly seen in sexually dysfunctional men due to improved patientapartner sexual success. There is no published data that suggests that sertaline has any direct biological effect on sexual desire which may explain this observation. Four men in the cohort of six men with severe primary PE who achieved intravaginal ejaculation for the ®rst time in their sexual life with treatment with sertraline had previously undergone and failed to respond to one or more trials of treatment with psychosexual counselling. These men must be considered as suffering from severe and refractory PE, and previous treatment failures. Sertraline drug treatment salvaged them from life long ejaculatory dysfunction and its relationship consequences.
Sertraline appears to be well tolerated by the men enrolled in this study although 14 men experienced anejaculation and declined further treatment with higher doses of 50 and 100 mg sertralinead. These 14 men had a mean pre-treatment ejaculatory interval of 1.9 min which is higher than that the entire study group (1.0 min) and as such, one would expect a lesser in-cidence of anejaculation if stricter selective criteria were used for drug treatment. Other side effects were minor and often transient and none prompted withdrawal from the study. The occurrence of other sexual adverse effects of erectile dysfunction and diminished libido was dose related, occurring only with 100 mg sertralinead.
Conclusions
Sertraline appears to be a useful and reasonably well tolerated oral treatment for premature ejaculation with improved ejaculatory control usually occurring within 1±2 weeks and subsequent increased freqency of intercourse. There appears to be a direct dose related increase in ejaculatory latency time which may result in anejaculation in some men with doses of 50 mg or higher.
